|
- A risk-based treatment strategy for non-rhabdomyosarcoma soft . . .
Summary Background Tumour grade, tumour size, resection potential, and extent of disease afect outcome in paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no risk stratification systems exist and the standard of care is poorly defined We developed a risk stratification system from known prognostic factors and assessed it in the context of risk-adapted therapy for young
- Soft tissue sarcoma in children, adolescents and young adults . . .
The aim is to describe and assess the 34 prognostic impact of initial management of STS according to the type of referring centers and 35 the number of optimal criteria 36 Methods: Monocentric retrospective analysis of the management of 127 youths (0-25 years) 37 with localized STS treated from 2006 to 2015
- Synovial Sarcoma Relapses in Children and Adolescents . . .
The key to good management of synovial sarcoma relapses in children and adolescents is microscopically complete surgical resection, as initial therapy whenever possible or after chemo-reduction
- Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Children: A . . .
Spunt SL, Poquette CA, Hurt YS, et al Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: An analysis of 121 patients treated at St Jude Chil-dren’s Research Hospital
- Grading of Nonrhabdomyosarcoma Soft Tissue Sarcoma in . . .
Spunt SL, Poquette CA, Hurt YS, et al Prognostic factors for children and adolescents with surgically resected non-rhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children’s Research Hospital
- Nonrhabdomyosarcoma Soft Tissue Sarcoma in Children . . .
Introduction Nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) are a large and very heterogeneous group of cancers in children Although approximately 550 NRSTS diagnoses in the US each year represent only approximately 4% of cases of childhood cancer, NRSTS comprise nearly 60% of all soft tissue sarcomas in this age group [reviewed in Spunt et al (2006)] The incidence is bimodally
- Outcomes following preoperative chemoradiation + - pazopanib . . .
Background: Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity in advanced soft tissue sarcoma ARST1321 was a phase II study designed to compare the near complete pathologic re-sponse rate (≥ 90% necrosis) following preoperative chemoradiation + - pazopanib in children and adults with intermediate high risk
|
|
|